Cargando…
Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma
Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been descri...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273411/ https://www.ncbi.nlm.nih.gov/pubmed/35832645 http://dx.doi.org/10.1155/2022/4015897 |
_version_ | 1784745067646287872 |
---|---|
author | Chen, Ying Zhuang, Lei Zhang, Danhong Du, Xianghui Sheng, Liming |
author_facet | Chen, Ying Zhuang, Lei Zhang, Danhong Du, Xianghui Sheng, Liming |
author_sort | Chen, Ying |
collection | PubMed |
description | Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been described. Herein, a retrospective study was conducted, which 82 patients with advanced metastatic or recurrent ESCC treated with camrelizumab were enrolled. Twenty patients (24.4%) experienced TD during camrelizumab treatment with or without chemotherapy. The median onset time of TD was 1.7 months. The incidence of TD was 35.6% in patients who previously received thoracic radiotherapy versus 10.8% in patients who did not (P =0.009). Patients with TD had significantly longer median progression-free survival (5.5 months vs 3.5 months, P =0.035) and overall survival (26.7 months vs 11.5 months, P <0.001). TD is frequently observed in ESCC patients treated with camrelizumab and especially in patients who received radiotherapy previously. ESCC patients with TD during ICIs treatment often have better prognosis. |
format | Online Article Text |
id | pubmed-9273411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92734112022-07-12 Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma Chen, Ying Zhuang, Lei Zhang, Danhong Du, Xianghui Sheng, Liming J Immunol Res Research Article Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been described. Herein, a retrospective study was conducted, which 82 patients with advanced metastatic or recurrent ESCC treated with camrelizumab were enrolled. Twenty patients (24.4%) experienced TD during camrelizumab treatment with or without chemotherapy. The median onset time of TD was 1.7 months. The incidence of TD was 35.6% in patients who previously received thoracic radiotherapy versus 10.8% in patients who did not (P =0.009). Patients with TD had significantly longer median progression-free survival (5.5 months vs 3.5 months, P =0.035) and overall survival (26.7 months vs 11.5 months, P <0.001). TD is frequently observed in ESCC patients treated with camrelizumab and especially in patients who received radiotherapy previously. ESCC patients with TD during ICIs treatment often have better prognosis. Hindawi 2022-07-04 /pmc/articles/PMC9273411/ /pubmed/35832645 http://dx.doi.org/10.1155/2022/4015897 Text en Copyright © 2022 Ying Chen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chen, Ying Zhuang, Lei Zhang, Danhong Du, Xianghui Sheng, Liming Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title_full | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title_fullStr | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title_full_unstemmed | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title_short | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
title_sort | thyroid dysfunction as a predictive indicator in camrelizumab of advanced esophageal squamous cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273411/ https://www.ncbi.nlm.nih.gov/pubmed/35832645 http://dx.doi.org/10.1155/2022/4015897 |
work_keys_str_mv | AT chenying thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT zhuanglei thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT zhangdanhong thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT duxianghui thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT shengliming thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma |